DRAGARWQ vs NEPHROPLUS: Stock Comparison

Dr Agarwals Eye Hospital Ltd vs Nephrocare Health Services LtdUpdated 25 Aug 26, 4:08 PM ISTNSE & company filings

Nephrocare Health Services Ltd is the larger company by market capitalisation. Dr Agarwals Eye Hospital Ltd shows a lower P/E, a higher ROE and a higher dividend yield, while Nephrocare Health Services Ltd shows lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

DRAGARWQ leads 7; NEPHROPLUS leads 4 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

DRAGARWQNEPHROPLUS

Valuation lens

What price are you paying?

Market CapContext only
₹2,588 Cr
₹6,991 Cr
P/E RatioDRAGARWQ has the lower reading
33.71x
89.97x
P/B RatioNEPHROPLUS has the lower reading
7.42x
6.19x
EPSDRAGARWQ has the higher reading
₹145
₹7.66
Book ValueContext only
₹717
₹111
Dividend YieldDRAGARWQ has the higher reading
0.13%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
NEPHROPLUS is the larger company
₹6,991 Cr vs ₹2,588 Cr
P/E Ratio
DRAGARWQ has a lower P/E
33.71x vs 89.97x
P/B Ratio
NEPHROPLUS has a lower P/B
6.19x vs 7.42x
EPS
DRAGARWQ has higher earnings per share
₹145 vs ₹7.66
Dividend Yield
DRAGARWQ has a higher dividend yield
0.13% vs 0%
Qtr Sales Growth
NEPHROPLUS has stronger quarterly sales growth
21.2% vs 20.2%
Qtr Profit Growth
NEPHROPLUS has stronger quarterly profit growth
22.1% vs 1.56%
ROE
DRAGARWQ has a higher ROE
25.2% vs 9.06%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Price

MetricDRAGARWQNEPHROPLUS
Live Price₹5,328.5₹697.35
Day Change-0.84%1.47%
Volume6491.46 L
52-Week High₹6,059.7₹769.75
52-Week Low₹4,600₹446
Distance from 52W High-12.07%-9.41%

Valuation

MetricDRAGARWQNEPHROPLUS
Market Cap₹2,588 Cr₹6,991 Cr
P/E Ratio33.71x89.97x
P/B Ratio7.42x6.19x
EPS₹145₹7.66
Book Value₹717₹111
Dividend Yield0.13%0%

Growth

MetricDRAGARWQNEPHROPLUS
Revenue Growth (TTM YoY)0%0%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth20.2%21.2%
Qtr Profit Growth1.56%22.1%

Profitability & Leverage

MetricDRAGARWQNEPHROPLUS
ROE25.2%9.06%
ROCE17.4%15.5%
Net Margin14.89%7.69%
Operating Margin30.9%22.4%
Debt to Equity0.94x0.07x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricDRAGARWQNEPHROPLUS
Promoter Holding72.67%21.07%
FII Holding2.24% 0.04 pp8.78% 1.16 pp
DII Holding2.05% 0.07 pp9.05% 0.4 pp
Public Holding23.04% 0.04 pp18.32% 0.76 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Dr Agarwals Eye Hospital Ltd and Nephrocare Health Services Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.